Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-21
2011-06-21
Kolker, Daniel E (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C514S005900
Reexamination Certificate
active
07964359
ABSTRACT:
The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric Aβ peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric Aβ peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric Aβ peptide assemblies, also known as ADDLs, and ADDL-related assemblies.
REFERENCES:
patent: 6313093 (2001-11-01), Frey, II
patent: 2008/0248099 (2008-10-01), Ishii
Alberts et al. 1994. Molecular Biology of the Cell, pp. 129-130.
Zhao et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci. Dec. 8, 2004;24(49):11120-6.
Hennige et al. Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes. Feb. 2005;54(2):361-6.
Rickle, Annika, “PTEN and AKT Signalling in Alzheimer's Disease”, Karolinska Institutet 2005—Thesis.
Arvanitakis et al., “Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function”, Arch Neurol 2004 61:661-666.
Ho et al., “Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease”, FASEB 2004 18(17):902-904.
Lacor et al., “Synaptic targeting by Alzheimer's-Related Amyloid Beta Oligomers”, The Journal of Neuroscience 2004 24(45):10191-10200.
Klein William L.
Krafft Grant A.
Zhao Wei-Qin
Acumen Pharmaceuticals, Inc.
Emch Gregory S
Kolker Daniel E
Licata & Tyrrell P.C.
Northwestern University
LandOfFree
Compositions and methods for the enhancement of soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the enhancement of soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the enhancement of soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691535